

Supplementary Table S1 Individualised maintenance dose

		PAH-CTD		PAH-SSc		PAH-SLE		PAH-MCTD/CTD-other	
Dose groups	Twice-daily dose	Placebo N=167 n (%)	Selexipag N=167 n (%)	Placebo N=93 n (%)	Selexipag N=77 n (%)	Placebo N=37 n (%)	Selexipag N=45 n (%)	Placebo N=37 n (%)	Selexipag N=45 n (%)
Low-dose group (200–400 µg)	200	6 (3.6)	15 (9.0)	5 (5.4)	11 (14.3)	0	0	1 (2.7)	4 (8.9)
	400	8 (4.8)	25 (15.0)	4 (4.3)	10 (13.0)	2 (5.4)	6 (13.3)	2 (5.4)	9 (20.0)
Medium-dose group (600–1000 µg)	600	6 (3.6)	19 (11.4)	2 (2.2)	9 (11.7)	3 (8.1)	4 (8.9)	1 (2.7)	6 (13.3)
	800	8 (4.8)	19 (11.4)	5 (5.4)	9 (11.7)	1 (2.7)	7 (15.6)	2 (5.4)	3 (6.7)
	1000	8 (4.8)	7 (4.2)	4 (4.3)	3 (3.9)	3 (8.1)	1 (2.2)	1 (2.7)	3 (6.7)
High-dose group (1200–1600 µg)	1200	6 (3.6)	10 (6.0)	2 (2.2)	4 (5.2)	1 (2.7)	4 (8.9)	3 (8.1)	2 (4.4)
	1400	14 (8.4)	14 (8.4)	8 (8.6)	7 (9.1)	3 (8.1)	5 (11.1)	3 (8.1)	2 (4.4)
	1600	108 (64.7)	51 (30.5)	60 (64.5)	21 (27.3)	24 (64.9)	17 (37.8)	24 (64.9)	13 (28.9)
Other than per-protocol dosing		2 (1.2)	1 (0.6)	2 (2.2)	1 (1.3)	0	0	0	0

One patient in the placebo group and six patients in the selexipag group had an individualised maintenance dose of 0 µg and are not reported here.

CTD: connective tissue disease; MCTD: mixed connective tissue disease; PAH: pulmonary arterial hypertension; SLE: systemic lupus erythematosus; SSc: systemic sclerosis.